The US Food and Drug Administration has granted approval to the inclusion of cardiovascular safety data from the DEVOTE trial in US prescribing information for Tresiba.
The US Food and Drug Administration has granted approval to the inclusion of cardiovascular safety data from the DEVOTE trial in US prescribing information for Tresiba.
The US Food and Drug Administration has granted approval to the inclusion of cardiovascular safety data from the DEVOTE trial in US prescribing information for Tresiba.
Following the success of the reSURFACE clinical program, the US Food and Drug Administration has approved a new treatment option for adults with moderate to severe plaque psoriasis.
Following the success of the reSURFACE clinical program, the US Food and Drug Administration has approved a new treatment option for adults with moderate to severe plaque psoriasis.